image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 0.79
-2.48 %
$ 2.53 M
Market Cap
-0.09
P/E
1. INTRINSIC VALUE

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.[ Read More ]

The intrinsic value of one AVGR stock under the base case scenario is HIDDEN Compared to the current market price of 0.79 USD, Avinger, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AVGR

image
FINANCIALS
7.65 M REVENUE
-7.51%
-16.6 M OPERATING INCOME
-4.25%
-18.3 M NET INCOME
-3.96%
-14.4 M OPERATING CASH FLOW
13.89%
-8 K INVESTING CASH FLOW
84.31%
5.11 M FINANCING CASH FLOW
-57.10%
1.65 M REVENUE
-10.67%
-3.67 M OPERATING INCOME
11.10%
-3.71 M NET INCOME
15.04%
-2.86 M OPERATING CASH FLOW
19.82%
0 INVESTING CASH FLOW
0.00%
-44 K FINANCING CASH FLOW
-0.85%
Balance Sheet Decomposition Avinger, Inc.
image
Current Assets 12.2 M
Cash & Short-Term Investments 5.28 M
Receivables 1.01 M
Other Current Assets 5.87 M
Non-Current Assets 1.61 M
Long-Term Investments 0
PP&E 1.59 M
Other Non-Current Assets 19 K
Current Liabilities 19.3 M
Accounts Payable 777 K
Short-Term Debt 15.4 M
Other Current Liabilities 3.13 M
Non-Current Liabilities 672 K
Long-Term Debt 0
Other Non-Current Liabilities 672 K
EFFICIENCY
Earnings Waterfall Avinger, Inc.
image
Revenue 7.65 M
Cost Of Revenue 5.65 M
Gross Profit 2 M
Operating Expenses 18.6 M
Operating Income -16.6 M
Other Expenses 1.68 M
Net Income -18.3 M
RATIOS
26.18% GROSS MARGIN
26.18%
-217.39% OPERATING MARGIN
-217.39%
-239.41% NET MARGIN
-239.41%
295.39% ROE
295.39%
-133.04% ROA
-133.04%
-205.60% ROIC
-205.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avinger, Inc.
image
Net Income -18.3 M
Depreciation & Amortization 1.39 M
Capital Expenditures -8 K
Stock-Based Compensation 940 K
Change in Working Capital 187 K
Others 2.14 M
Free Cash Flow -14.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avinger, Inc.
image
AVGR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
27.78% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Avinger, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Mar 23, 2023
Sell 181 USD
Subainati Nabeel Paul
Vice President, Finance
- 223
0.8113 USD
2 years ago
Nov 30, 2021
Sell 105 USD
CULLEN JAMES
Director
- 184
0.57 USD
2 years ago
Nov 24, 2021
Sell 19.8 USD
CULLEN JAMES
Director
- 32
0.62 USD
4 years ago
Sep 22, 2020
Sell 3.02 K USD
SOINSKI JEFFREY M
Chief Executive Officer
- 9145
0.3305 USD
4 years ago
Sep 22, 2020
Sell 2.02 K USD
Patel Himanshu
Chief Technology Officer
- 6097
0.3305 USD
4 years ago
Sep 22, 2020
Sell 2.02 K USD
WEINSWIG MARK
Chief Financial Officer
- 6097
0.3305 USD
4 years ago
Sep 08, 2020
Sell 2.42 K USD
SOINSKI JEFFREY M
Chief Executive Officer
- 5982
0.4047 USD
4 years ago
Sep 08, 2020
Sell 1.21 K USD
WEINSWIG MARK
Chief Financial Officer
- 2991
0.4047 USD
4 years ago
Sep 08, 2020
Sell 1.45 K USD
Patel Himanshu
Chief Technology Officer
- 3589
0.4047 USD
6 years ago
Feb 16, 2018
Bought 50 K USD
Patel Himanshu
CTO
+ 25000
2 USD
6 years ago
Feb 16, 2018
Bought 50 K USD
Patel Himanshu
CTO
+ 25000
2 USD
6 years ago
Feb 16, 2018
Bought 50 K USD
Patel Himanshu
CTO
+ 50
1000 USD
7 years ago
Nov 13, 2017
Sell 121 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 454584
0.2667 USD
7 years ago
Nov 14, 2017
Sell 30.4 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 118897
0.2554 USD
7 years ago
Nov 15, 2017
Sell 113 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 500649
0.226 USD
8 years ago
Aug 16, 2016
Bought 200 K USD
SOINSKI JEFFREY M
Chief Executive Officer
+ 57100
3.5 USD
8 years ago
Aug 16, 2016
Bought 24.5 K USD
Ferguson Matthew
Chief Financial Officer
+ 7000
3.5 USD
8 years ago
Jul 20, 2016
Sell 204 K USD
Simpson John D.
Sr. VP, Sales & Marketing
- 32500
6.2777 USD
8 years ago
Jul 20, 2016
Sell 204 K USD
Simpson John D.
Sr. VP, Sales & Marketing
- 32500
6.2777 USD
8 years ago
May 06, 2016
Sell 117 K USD
Lucas Donald A
Director
- 9309
12.5789 USD
8 years ago
May 06, 2016
Sell 134 K USD
Patel Himanshu
CTO
- 10000
13.4 USD
8 years ago
Apr 15, 2016
Sell 985 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 75111
13.1076 USD
8 years ago
Mar 11, 2016
Bought 11.3 K USD
Ferguson Matthew
director: Chief Financial Officer
+ 1000
11.3 USD
8 years ago
Mar 11, 2016
Bought 11.3 K USD
Ferguson Matthew
Chief Financial Officer
+ 1000
11.3 USD
8 years ago
Mar 11, 2016
Bought 5.75 K USD
Ferguson Matthew
Chief Financial Officer
+ 500
11.5 USD
8 years ago
Mar 11, 2016
Bought 5.75 K USD
Ferguson Matthew
director: Chief Financial Officer
+ 500
11.5 USD
8 years ago
Mar 11, 2016
Sell 458 K USD
SIMPSON JOHN B PH D MD
director: Executive Chairman
- 40000
11.4382 USD
8 years ago
Dec 14, 2015
Sell 8.22 K USD
Lucas Donald A
director, 10 percent owner:
- 500
16.438 USD
8 years ago
Dec 14, 2015
Sell 8.26 K USD
Lucas Donald A
director, 10 percent owner:
- 500
16.5258 USD
8 years ago
Dec 14, 2015
Sell 8.11 K USD
Lucas Donald A
director, 10 percent owner:
- 500
16.2288 USD
8 years ago
Dec 14, 2015
Sell 7.95 K USD
Lucas Donald A
director, 10 percent owner:
- 500
15.9048 USD
8 years ago
Dec 14, 2015
Sell 8.01 K USD
Lucas Donald A
director, 10 percent owner:
- 500
16.0131 USD
8 years ago
Dec 14, 2015
Sell 3.03 K USD
Lucas Donald A
director, 10 percent owner:
- 188
16.1265 USD
8 years ago
Dec 14, 2015
Sell 9.39 K USD
Lucas Donald A
director, 10 percent owner:
- 592
15.8652 USD
8 years ago
Dec 11, 2015
Sell 7.93 K USD
Lucas Donald A
director, 10 percent owner:
- 500
15.857 USD
8 years ago
Dec 11, 2015
Sell 7.94 K USD
Lucas Donald A
director, 10 percent owner:
- 500
15.8715 USD
8 years ago
Dec 11, 2015
Sell 8.03 K USD
Lucas Donald A
director, 10 percent owner:
- 500
16.0682 USD
8 years ago
Dec 11, 2015
Sell 7.9 K USD
Lucas Donald A
director, 10 percent owner:
- 500
15.7951 USD
8 years ago
Dec 11, 2015
Sell 15.9 K USD
Lucas Donald A
director, 10 percent owner:
- 1000
15.9279 USD
8 years ago
Dec 11, 2015
Sell 4.78 K USD
Lucas Donald A
director, 10 percent owner:
- 300
15.93 USD
8 years ago
Dec 11, 2015
Sell 3.19 K USD
Lucas Donald A
director, 10 percent owner:
- 200
15.95 USD
8 years ago
Dec 11, 2015
Sell 1.6 K USD
Lucas Donald A
director, 10 percent owner:
- 100
16 USD
8 years ago
Dec 11, 2015
Sell 1.03 K USD
Lucas Donald A
director, 10 percent owner:
- 65
15.89 USD
8 years ago
Dec 11, 2015
Sell 556 USD
Lucas Donald A
director, 10 percent owner:
- 35
15.9 USD
8 years ago
Dec 11, 2015
Sell 3.2 K USD
Lucas Donald A
director, 10 percent owner:
- 200
15.99 USD
8 years ago
Dec 11, 2015
Sell 1.6 K USD
Lucas Donald A
director, 10 percent owner:
- 100
16 USD
8 years ago
Nov 24, 2015
Sell 730 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 42445
17.203 USD
8 years ago
Nov 25, 2015
Sell 996 K USD
SIMPSON JOHN B PH D MD
Executive Chairman
- 57555
17.2978 USD
9 years ago
Feb 04, 2015
Sell 60 K USD
Lucas Donald A
director, 10 percent owner:
- 4615
13 USD
9 years ago
Feb 04, 2015
Sell 318 K USD
Lucas Donald A
director, 10 percent owner:
- 24487
13 USD
9 years ago
Feb 04, 2015
Sell 30 K USD
CULLEN JAMES
Director
- 2307
13 USD
9 years ago
Feb 04, 2015
Sell 22.5 K USD
Patel Himanshu
Chief Technology Officer
- 1731
13 USD
9 years ago
Feb 04, 2015
Sell 7.5 K USD
MCELWEE JAMES B
Director
- 577
13 USD
9 years ago
Feb 04, 2015
Sell 15 K USD
Ferguson Matthew
Chief Business Officer and CFO
- 1154
13 USD
7. News
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript Avinger, Inc. (NASDAQ:AVGR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call. seekingalpha.com - 1 week ago
Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago. zacks.com - 1 week ago
Avinger Reports Third Quarter 2024 Results Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024. Third Quarter and Recent Highlights Reported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%. accesswire.com - 1 week ago
Avinger to Announce Third Quarter 2024 Results on November 7, 2024 REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET. accesswire.com - 2 weeks ago
Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad. accesswire.com - 3 weeks ago
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications. accesswire.com - 1 month ago
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology. zacks.com - 2 months ago
Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of the Pantheris LV image-guided directional atherectomy system. With the initiation of full commercial launch, all current and prospective accounts can now order the Pantheris LV device, a line extension of the first and only image-guided atherectomy device for the treatment of peripheral artery disease (PAD). accesswire.com - 2 months ago
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript seekingalpha.com - 3 months ago
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates Avinger (AVGR) came out with a quarterly loss of $2.82 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $8.85 per share a year ago. zacks.com - 3 months ago
Avinger Reports Second Quarter 2024 Results Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission REDWOOD CITY, CA / ACCESSWIRE / August 8, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights Reported second quarter 2024 revenue of $1.8 million, with a sequentially increased gross margin of 20% Streamlined operating costs in June 2024 to provide support for its existing peripheral user base while advancing coronary product line development, with the full effect of the cost reductions expected to be seen in the second half of 2024 Continued Phase III verification and validation studies for Avinger's proprietary image-guided coronary CTO-crossing system for IDE submission anticipated in the third quarter of 2024 Building product inventory for full commercial launch of the new Pantheris LV (large vessel) image-guided atherectomy device in the coming weeks Announced the appointment of Thomas Davis, MD, FACC, a highly experienced interventional cardiologist and pre-eminent leader in the treatment of vascular disease, as Chief Medical Officer Completed the conversion of $11 million of debt into shares of a new series of convertible preferred stock, reducing the outstanding principal amount of debt to $2.6 million with no principal payments until 2027 Secured up to $24 million in additional growth financing, with $6 million funded in June 2024 and up to an additional $18 million available based upon the exercise in full of coronary clinical milestone-linked warrants "The Phase III verification and validation studies for our innovative coronary CTO solution remain on track for filing an IDE application by the end of the third quarter," said Jeff Soinski, Avinger's President and CEO. accesswire.com - 3 months ago
Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. accesswire.com - 3 months ago
8. Profile Summary

Avinger, Inc. AVGR

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 2.53 M
Dividend Yield 27.78%
Description Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Contact 400 Chesapeake Drive, Redwood City, CA, 94063 https://avinger.com
IPO Date Jan. 30, 2015
Employees 71
Officers Dr. Jaafer Golzar FACC, M.D. Chief Medical Officer Mr. Philip R. Preuss Chief Commercial Officer Mr. Himanshu N. Patel Chief Technology Officer Mr. Keith Schaefer Chief Operating Officer